Studies on lysophosphatidylcholine (LPC), a gut microbiome-derived molecule, indicate its ability to improve AD pathology by inhibiting ACSL4 [150], hinting at its potential for neuroprotection in PD. The gene discussed is ACSL4; the disease is Parkinson disease.